FrancophonIA/ELRC3.0 huggingface dataset:
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is an antiviral medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan on viirusravim, mida kasutatakse inimese immuunpuudulikkuse I tüübi viirusega (HIV1) nakatunud täiskasvanute raviks; HIV1 põhjustab omandatud immuunpuudulikkuse sündroomi (AIDS).
English: The full EPAR can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Atripla, and do not need to be repeated for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan.
Estonian: Võrdlusravimiga Atripla on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan korrata.
English: Because Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan keeps the amount of HIV in the blood at a low level.
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan hoiab HIV-sisalduse veres väikese.
English: What is Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan and what is it used for?
Estonian: Mis on Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan ja milleks seda kasutatakse?
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan efavirenz / emtricitabine / tenofovir disoproxil
Estonian: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan efavirens/emtritsitabiin/tenofoviirdisoproksiil
English: For practical information about using Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The company that markets the medicine will ensure that all doctors expected to prescribe the medicine are provided with an educational pack that includes information on the increased risk of kidney disease with medicines containing tenofovir disoproxil such as this one.
Estonian: Ravimi turustaja varustab kõik ravimit määravad arstid teabepakmega, mis sisaldab teavet neeruhaiguse suurenenud riski kohta tenofoviirdisoproksiili sisaldavate ravimitega nagu Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan.
English: Recommendations and precautions to be followed by healthcare professionals and patients for its safe and effective use have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The European Medicines Agency concluded that, in accordance with EU requirements, the medicine has been shown to have comparable quality and to be bioequivalent to Atripla.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Atripla.
English: Other information about Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan
Estonian: Muu teave ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan kohta
English: This is a summary of the European public assessment report (EPAR) for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan.
Estonian: See on ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that it contains the same active substances and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Atripla.
Estonian: See tähendab, et Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan sisaldab samu toimeaineid ja toimib samal viisil kui võrdlusravim Atripla, millel juba on Euroopa Liidus müügiluba.
English: For more information about treatment with this medicine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan on 5 September 2017.
Estonian: Ravimiamet soovitas ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan kasutamise Euroopa Liidus heaks kiita.
English: Therefore, the Agency's view was that, as for Atripla, the benefit outweighs the identified risk.
Estonian: Seetõttu on ravimiamet arvamusel, et nagu ka Atripla korral, ületab ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan kasulikkus sellega kaasnevad riskid.
English: What measures are being taken to ensure the safe and effective use of this medicine?
Estonian: Mis meetmed võetakse, et tagada ravimi Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan ohutu ja efektiivne kasutamine?
English: Inactivated poliomyelitis virus (IPV): type 1
Estonian: Inaktiveeritud poliomüeliidi viiruseid (IPV): Tüüp 1
English: Recombinant hepatitis B surface antigen, S (HBsAg)
Estonian: Hepatiit B pinnaantigeeni (HBsAg)
English: EU Number Invented name Strength Pharmaceutical formRoute of administration Packaging
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu Pakendi suurus
English: 1 Monodose preparation of 0.5 ml contains: Purified diptheria toxoid, adsorbed (PDT)
Estonian: 1 Üks annus ( 0,5 ml) sisaldab: Puhastatud absorbeeritud difteeria toksoidi (PDT)
English: Haemophilus influenzae polysaccharide type b conjugated to tetanus protein (PRP-T)
Estonian: Haemophilus influenzae tüüp b polüsahhariidi konjugeeritud teetanuse toksoidile (PRP-T)
English: Content Package size
Estonian: Müügiloa nr Euroopa Liidus
English: Purified pertussis toxoid, adsorbed (PTxd)
Estonian: Puhastatud absorbeeritud läkaköha toksoidi (PTxd)
English: Purified filamentous haemagglutinin adsorbed (FHA)
Estonian: Puhastatud läkaköha filamentoosset hemaglutiniini (FHA)
English: 1 syringe without attached needle
Estonian: 1 süstel ilma nõelata
English: Purified tetanus toxoid, adsorbed (PTT)
Estonian: Puhastatud absorbeeritud teetanuse toksoidi (PTT)
English: 1 syringe with attached needle
Estonian: 1 süstel koos nõelaga
English: What measures are being taken to ensure the safe and effective use of Ruconest?
Estonian: Mis meetmed võetakse, et tagada Ruconesti ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ruconest on 28 October 2010.
Estonian: Euroopa Komisjon andis Ruconesti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. oktoobril 2010.
English: Other information about Ruconest
Estonian: Muu teave Ruconesti kohta
English: It is given by slow injection into a vein lasting around five minutes.
Estonian: Seda manustatakse aeglase, ligikaudu viis minutit kestva veenisüstena.
English: Patients may be able to inject the medicine themselves after they have been properly trained.
Estonian: Patsient tohib süstida ravimit ka ise, kui ta on saanud asjakohase väljaõppe.
English: A patient should not be given more than two injections within any 24-hour period.
Estonian: 24 tunni jooksul ei tohi patsiendile manustada üle kahe süsti.
English: What is Ruconest and what is it used for?
Estonian: Mis on Ruconest ja milleks seda kasutatakse?
English: The full EPAR for Ruconest can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ruconesti kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: Why is Ruconest approved?
Estonian: Miks Ruconest heaks kiideti?
English: The most common side effect with Ruconest (seen in between 1 and 10 patients in 100) is headache.
Estonian: Ruconesti kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on peavalu.
English: The company will also provide prescribers with an alert card for their patients.
Estonian: Samuti annab tootja neile patsientide hoiatuskaardi.
English: Improvement was measured by the patients rating the severity of their symptoms on a scale from 0 to 100.
Estonian: Leevenemist mõõdeti selle järgi, kuidas patsiendid hindasid sümptomite raskusastet 0-100 punkti skaalal.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ruconest have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ruconesti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Patients receiving placebo started to improve after four hours in one study and after over eight hours in the other.
Estonian: Platseeborühma patsientidel hakkasid sümptomid leevenema ühes uuringus 4 tunni pärast ja teises uuringus rohkem kui 8 tunni pärast.
English: What is the risk associated with Ruconest?
Estonian: Mis riskid Ruconestiga kaasnevad?
English: The CHMP decided that Ruconest's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Ruconesti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: In this case the powder that comes with the solvent should be used.
Estonian: Sel juhul tuleb kasutada pulbrit, mida turustatakse koos lahustiga.
English: Ruconest must not be used in patients with known or suspected allergy to rabbits.
Estonian: Ruconesti ei tohi kasutada patsiendid, kes on teadaolevalt küülikute suhtes allergilised või kellel seda allergiat kahtlustatakse.
English: This is a summary of the European public assessment report (EPAR) for Ruconest.
Estonian: See on ravimi Ruconest Euroopa avaliku hindamisaruande kokkuvõte.
English: The main measure of effectiveness was how long it took for the symptoms to start to improve.
Estonian: Efektiivsuse põhinäitaja oli aeg sümptomite leevenemise alguseni.
English: One injection is usually enough to treat an attack, but a second injection may be given if the patient does not improve enough after the first one.
Estonian: Tavaliselt piisab episoodi raviks ühest süstist, kuid kui patsiendi seisund pärast esimest süsti ei parane, võib manustada ka teise süsti.
English: For more information about treatment with Ruconest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ruconestiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Ruconest was studied in two main studies involving a total of 70 adults and adolescents with hereditary angioedema caused by low levels of C1 esterase inhibitor protein.
Estonian: Ruconesti uuriti kahes põhiuuringus, milles osales kokku 70 täiskasvanut ja noorukit, kellel oli C1esteraasiinhibiitori väikesest sisaldusest põhjustatud pärilik angioödeem.
English: Ruconest is a medicine used to treat attacks of hereditary angioedema in adults and adolescents.
Estonian: Ruconest on ravim, mida kasutatakse päriliku angioödeemi episoodide raviks täiskasvanutel ja noorukitel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ruconest.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Ruconest conestat alfa
Estonian: Ruconest alfakonestaat
English: Ruconest contains the active substance conestat alfa.
Estonian: Ruconest sisaldab toimeainena alfakonestaati.
English: Patients receiving Ruconest at doses of 50 units/kg and 100 units/kg started to improve after one and two hours.
Estonian: Ruconesti annuses 50 ühikut/kg ja 100 ühikut/kg kasutanud patsientidel hakkasid sümptomid leevenema 1 ja 2 tunni pärast.
English: When it is given during an angioedema attack, conestat alfa stops this excessive activity, helping to relieve the patient's symptoms.
Estonian: Angioödeemi episoodi ajal manustatud alfakonestaat peatab nende süsteemide liigse aktiivsuse ning leevendab patsiendi sümptomeid.
English: How is Ruconest used?
Estonian: Kuidas Ruconesti kasutatakse?
English: The active substance in Ruconest, conestat alfa, is a copy of the C1 esterase inhibitor protein and wor ks in the same way as the natural human protein.
Estonian: Ruconesti toimeaine alfakonestaat on C1-esteraasiinhibiitori koopia ja toimib samamoodi kui looduslik inimvalk.
English: How does Ruconest work?
Estonian: Kuidas Ruconest toimib?
English: The C1 esterase inhibitor protein is required to control the ‘complement' and ‘contact' systems, collections of proteins in the blood that fight against infection and cause inflammation.
Estonian: C1-esteraasiinhibiitor juhib organismis komplemendi- ja kontaktisüsteeme - need on veres esinevad valgukogumid, mis võitlevad infektsiooni (nakkuse) vastu ja tekitavad põletikku.
English: The company that markets Ruconest will ensure that healthcare professionals who are expected to prescribe Ruconest are provided with an educational pack containing information on the proper use of the medicine and warnings about the risk of allergy.
Estonian: Ruconesti turustaja tagab, et kõikides Euroopa Liidu liikmesriikides saavad Ruconesti-ravi eeldatavasti määravad tervishoiutöötajad teabepakme, milles on ravimi õige kasutamise teave ja allergiariski hoiatus.
English: Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain.
Estonian: Angioödeemiga patsientidel võivad ebamugavust ja valu tekitavad turseepisoodid esineda kõikjal: näol, jäsemetel, soole ümbruses.
English: Patients with low levels of this protein have excessive activity of these two systems, which leads to the symptoms of angioedema.
Estonian: Patsientidel, kelle veres on C1-inhibiitorvalku vähe, on mõlema süsteemi aktiivsus liiga suur, mis põhjustab angioödeemi
English: Ruconest can only be obtained with a prescription and treatment should be started under the supervision of a doctor with experience in diagnosing and treating hereditary angioedema.
Estonian: Ruconest on retseptiravim ning ravi tohib alustada ainult päriliku angioödeemi ravikogemusega arsti järelevalve all.
English: Ruconest is used in patients with hereditary angioedema that is linked to naturally low levels of a protein called ‘C1 esterase inhibitor'.
Estonian: Ruconesti kasutatakse patsientidel, kelle pärilik angioödeem on seotud teatud valgu (C1-esteraasiinhibiitori) looduslikult väikese sisaldusega.
English: When an attack occurred, the patients were given Ruconest or placebo (a dummy treatment).
Estonian: Angioödeemi episoodi tekkimisel manustati patsiendile Ruconesti või platseebot (näiv ravim).
English: What benefits of Ruconest have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ruconesti kasulikkus?
English: For the full list of all side effects reported with Ruconest, see the package leaflet.
Estonian: Ruconesti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Ruconest was more effective than placebo at improving the symptoms of patients having an attack of angioedema.
Estonian: Angioödeemi episoodi sümptomite leevendamisel oli Ruconest efektiivsem kui platseebo.
English: Ruconest is available as a powder (with or without solvent) that is made up into a solution for injection.
Estonian: Ruconesti turustatakse süstelahuse pulbrina (koos lahustiga või ilma).
English: This mechanism takes place at high concentrations.
Estonian: See mehhanism toimib suurtel kontsentratsioonidel.
English: Over 50 different enzymes have been identified.
Estonian: Kindlaks on tehtud üle 50 ensüümi.
English: The interpretation of the EU legislation and consideration of compliance with the legal provisions of Article 6(3) of the Directive are not within the remit of the Committee and therefore these issues are not addressed in the assessment of the referral procedure.
Estonian: Euroopa Liidu õigusaktide tõlgendamine ja vastavuse hindamine direktiivi artikli 6 lõike 3 sätetega ei ole komitee pädevuses, mispärast neid küsimusi esildismenetluse hindamises ei käsitleta.
English: Croatia Krka - Farma d.o.o.
Estonian: Krka - Farma d.o.o.
English: 1 VICH GL 43: Guideline on target animal safety for veterinary pharmaceutical products http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004361.pdf
Estonian: 1 VICH GL 43: Guideline on target animal safety for veterinary pharmaceutical products http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004361.pdf et bakteriaalne MIC on ≤2 µg/ml.
English: Croatia PROPHARMA VET d.o.o.
Estonian: PROPHARMA VET d.o.o.
English: The scope of referral procedures is limited to evaluation of quality, safety and efficacy of veterinary medicinal products.
Estonian: Esildismenetluste kohaldamisala piirdub veterinaarravimite kvaliteedi, ohutuse ja efektiivsuse hindamisega.
English: Referral procedures on the basis of Article 35 of Directive 2001/82/EC require a clearly formulated question referred to the Committee.
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohastes esildismenetlustes nõutakse, et komiteele saadetakse selgesti sõnastatud küsimus.
English: ATCvet code: QJ01GB03
Estonian: ATCvet kood: QJ01GB03
English: Since the reference product is only authorised in Ireland, the concept of the European reference product has been applied in this MRP.
Estonian: Et võrdlusravim on heaks kiidetud ainult Iirimaal, kohaldati selles vastastikuse tunnustamise menetluses Euroopa võrdlusravimi mõistet.
English: Most of the injectable products for horses containing gentamicin were initially approved in the 1980s and 1990s, and (compared to current requirements) only very limited data are available to support indications or dosing regimens in horses.
Estonian: Enamik hobustele ette nähtud gentamütsiini sisaldavaid süsteravimeid kiideti esmakordselt heaks 1980. ja 1990. aastatel ning (võrreldes praeguste nõuetega) on olemas ainult väga piiratud andmed, mis toetavad näidustusi või annustamisrežiime hobustel.
English: The CVMP notes that pursuant to Article 36 of the Directive, its obligation is to consider the matter concerned and issue a reasoned opinion within the appropriate time limit.
Estonian: Veterinaarravimite komitee märgib, et direktiivi artikli 36 kohaselt on tema ülesanne teemat arutada ja esitada ettenähtud aja jooksul põhjendatud arvamus.
English: Spain LABIANA LIFE SCIENCE, S.A. C/ Venus, 26
Estonian: LABIANA LIFE SCIENCE, S.A. C/ Venus, 26
English: Spain CENAVISA Camí Pedra Estela s/n 43205 Reus Tarragona) Spain
Estonian: Camí Pedra Estela s/n 43205 Reus Tarragona) Hispaania
English: Spain Industrial Veterinaria, S.A. Esmeralda, 19
Estonian: Industrial Veterinaria, S.A. Esmeralda, 19
English: The Committee concluded that most of the current broad indications would not be supported by data.
Estonian: Komitee järeldas, et andmed ei toeta enamikku praegustest üldistest näidustustest.
English: The marketing authorisations of the products concerned by this referral procedure are assumed to have been granted by the national competent authorities on the basis of Article 6(3) of Directive 2001/82/EC.
Estonian: Esildismenetluses käsitletavate ravimite müügiload eeldatavasti andnud riiklikud pädevad asutused direktiivi 2001/82/EÜ artikli 6 lõike 3 alusel.
English: With relation to the already approved target species horses, the wording below should be used:
Estonian: Seoses hobuse kui juba heaks kiidetud loomaliigiga tuleb kasutada alljärgnevat sõnastust:
English: 43206 Tarragona Spain
Estonian: 43206 Tarragona Hispaania
English: Spain B.BRAUN VETCARE, S.A. Crta.
Estonian: B.BRAUN VETCARE, S.A. Crta.
English: The substance is highly polar, hydrophilic and transport appears to be an active process closely linked to electron transport, oxidative phosphorylation and the respiratory quinones in the cell membrane.
Estonian: Aine on väga polaarne, hüdrofiilne ja transport näib olevat aktiivne protsess, mis on tihedalt seotud elektronide transpordi, oksüdatiivse fosforüülimise ja rakumembraani respiratoorsete kinoonidega.
English: Latvia Huvepharma AD 33 James Boucher Blvd. Sofia 1407
Estonian: Huvepharma AD 33 James Boucher Blvd. Sofia 1407
English: Ozzano Emilia (Bologna) Italy
Estonian: Ozzano Emilia (Bologna) Itaalia
English: The reference product is Gentaject 10% solution for injection for horses which has been authorised in Ireland since 1988 (VPA 10976/2/1; Franklin Pharmaceuticals Ltd).
Estonian: Võrdlusravim on Gentaject 10% süstelahus hobustele, millel on Iirimaal müügiluba alates 1988. aastast (VPA 10976/2/1; Franklin Pharmaceuticals Ltd).
English: To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid under- or over-dosing.
Estonian: Õige annuse tagamiseks tuleb võimalikult täpselt määrata kehamass, et vältida ala- või üleannustamist.
English: There are insufficient data available to support the currently approved indications.
Estonian: Praegu heaks kiidetud näidustuste toetuseks kättesaadavad andmed on ebapiisavad.
English: Tarrasa, 121
Estonian: Tarrasa, 121 Rubí
English: As only very limited data are available to support all the current indications in horses the CVMP focused in their review mainly on the assessment of current scientific literature and minimum inhibitory concentration (MIC) data.
Estonian: Et olemas on ainult väga piiratud andmed, mis toetavad kõiki praeguseid näidustusi hobustel, keskendus veterinaarravimite komitee läbivaatamises peamiselt praegusele teaduskirjandusele ja minimaalse inhibeeriva kontsentratsiooni (MIC) andmetele.
English: Thus, the use of these products may present a serious risk to animal health in terms of lack of efficacy, as well as target animal safety.
Estonian: Seega võib nende ravimite kasutamine ohustada loomatervist nii vähese efektiivsuse kui ka sihtloomade ohutuse seisukohast.
English: C/ Prudenci Bertrana, 5 Polígono Industrial Agro-Reus Reus
Estonian: C/ Prudenci Bertrana, 5 Polígono Industrial AgroReus
English: The approved dosing regimens vary widely, ranging between doses of 2-10 mg/kg bw at intervals of 8-24 hours over 3-5 days.
Estonian: Heakskiidetud annustamisrežiimid on väga erinevad, varieerudes vahemikus 2-10 mg/kg 8-24-tunnise intervalliga 3-5 päeva.
English: All other dosing regimens appear to be approved based on expert reports, scientific publications and PK/PD characteristics.
Estonian: Näib, et kõik teised annustamisrežiimid on heaks kiidetud eksperdiaruannete, teaduslike publikatsioonidele ning farmakokineetika ja farmakodünaamika omaduste alusel.
English: Gentamicin is used for first or second choice treatments in a variety of clinical situations in horses.
Estonian: Gentamütsiini kasutatakse esimese või teise valiku ravimina mitme kliinilise seisundi raviks hobustel.